Aug 08, 2023 13:39 JST

Source: NEC Corporation

Aichi Cancer Center and NEC Develop an Efficient Method for Identifying Lung Cancer Antigens and Antigen-Specific T Cells
- Aichi Cancer Center and NEC developed a method for efficiently identifying lung cancer antigens (oncology marks) and antigen-specific T cells by combining single-cell analysis (1) of Tumor Infiltrating Lymphocytes (TIL) and NEC's AI-based antigen prediction system.
- Aichi Cancer Center and NEC clarified the characteristics of T cells that specifically recognize antigens.
- This study is expected to provide useful information for antigen-specific cancer vaccine therapy and engineered T cell therapy.

TOKYO, Aug 08, 2023 - (JCN Newswire) - Aichi Cancer Center and NEC Corporation's research group with Gifu University, Toyama University and Kitasato University Medical Center, have developed a method for efficiently identifying the lung cancer antigens and the antigen-specific T cells that recognize the antigens through both a single-cell analysis of Tumor Infiltrating Lymphocytes (TILs) and NEC's AI-based antigen prediction system that predicts immune response. Our paper describing the results of this study was published on August 6, 2023 in the "Journal for ImmunoTherapy of Cancer," which is the official journal of the Society of Immunotherapy of Cancer (SITC) in the United States.

Figure 1. Overall scheme of this Study

Figure 2. The uniform manifold approximation and projection (UMAP) of the expression profiles of the 6,998 TILs derived from the three surgical lung tumor tissues. TILs are classified into 10 distinct clusters.

Figure 3. A total of five tumor antigens (KK-LC-1, mutant SORL1, mutant JAGN1, mutant AKT2, mutant ITGB5) and nine tumor antigen-specific TCRs (shown in different colors, 140 TCR clones in total) were identified.

Figure 4. (A) Re-clustering of TCR clones (n=140) that express nine TCRs. (B) The expression analysis of T cell subset-defining genes in each antigen.

Research Background

Lung cancer is one of the most common cancers and one of the leading causes of cancer death worldwide. There are many types of cancer treatment, such as surgery, chemotherapy, radiation therapy, molecular targeted therapy, immunotherapy, and combinations of these. Recently developed immune checkpoint inhibitors (ICI) have attracted attention as a new therapy, and lung cancer is one of the most sensitive cancers to ICI, but it is effective in only a subset of individuals. Accordingly, new effective immunotherapies are required for lung cancer.

Cytotoxic T lymphocytes (CTLs) in TIL are crucial immune cells that can specifically recognize and eliminate tumor cells. Antigens targeted by CTL include patient-specific neoantigens and common antigens commonly expressed among patients such as cancer-testis antigens (CTA). In general, it is not easy to identify any antigens. If these antigens can be efficiently identified, a combination therapy with ICIs and antigen-specific immunotherapy may enhance the efficacy of treatment.

Contents and results of this research

In this study by Aichi Cancer Center and NEC, we performed a single-cell analysis to determine the TILs characteristics of patients with surgically resected non-small cell lung cancer (NSCLC) (n=3) (Figure. 1). Then, we divided the TILs into 10 clusters based on gene expression profile, and identified the exhausted T cell cluster (Tex cluster) characterized by the expression of the genes called exhaustion markers (Figure. 2). We synthesized the TCRs contained in the identified exhausted T cell cluster and induced each of the TCRs into each corresponding T cell, and examined the immune responses to neoantigens predicted by NEC's AI-based antigen prediction system and typical CTAs. It was confirmed that NEC's AI-based antigen prediction system can accurately predict the antigens that cause the immune responses, and we identified four TCRs recognizing KK-LC-1 (one of the CTAs, *2), and five TCRs recognizing the neoantigens (Figure. 3).

Researcher's comment

Dr. Hirokazu Matsushita, Chief, Division of Translational Oncoimmunology, Aichi Cancer Center
In collaboration with NEC and leading research institutes, the Aichi Cancer Center has developed a procedure for efficiently identifying antigens and antigen-specific T cells using surgical samples from patients with cancer. Looking ahead, we will add a spatial analysis of the cancer microenvironment that contains antigens and antigen-specific T-cells to this system to further clarify the nature of the T-cells infiltrating the cancer. In addition to aiming to develop innovative cancer immunotherapies from these studies, we will apply the knowledge gained to other cancers as well.

Yoshiko Yamashita, Ph.D. Senior Professional, AI Drug Development Division, NEC Corporation
NEC is conducting clinical trials of personalized cancer vaccine therapies targeting neoantigens. We believe that we have taken a step forward in realizing even more sophisticated personalized cancer vaccine immunotherapies and engineered T cell therapies by using a method to identify antigen-specific T cells constructed in this study and an Attentive Variational Information Bottleneck (AVIB) method (*3) to predict interactions between TCRs and antigens using AI newly developed by NEC. We will continue to accelerate research and development to provide effective treatments to patients.

Research support
Aichi Cancer Center Priority Project Research
NEC Corporation
Subsidy Program for Scientific Research by the Japan Society for the Promotion of Science
Japan Respiratory Foundation
Uehara Memorial Life Science Foundation

(1) Single-cell analysis is an analysis method that is capable of detecting RNA, which is a DNA transfer product for each cell, rather than as a mass of tissue, and understanding the individuality and diversity of individual cells based on the level of gene expression.
(2) KK-LC-1 (KitaKyushu Lung Canner antigen-1): Cancer and testis antigens that have been reported to be expressed in cancer.
(3) Attentive Variational Information Bottleneck (AVIB) Method: Variation information bottleneck method developed by NEC Laboratories Europe and NEC Laboratories America to predict interactions between TCRs and antigens using AI. (

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at

Source: NEC Corporation
Sectors: Healthcare & Pharm, MedTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

NEC and Ursa Space collaborate on satellite image analysis services using one of the world's largest virtual constellations
June 20 2024 12:20 JST
NEC hosts New Zealand Prime Minister Christopher Luxon
June 19 2024 18:00 JST
NEC develops compact millimeter-wave distributed antenna for Beyond 5G/6G through the development of a radio-over-fiber system enabling low power consumption
June 17 2024 15:06 JST
NEC announces external appointment of executive personnel
June 05 2024 16:43 JST
Successful demonstration of a superconducting circuit for qubit control within large-scale quantum computer systems
June 03 2024 17:58 JST
Celonis and NEC begin Proof of Concept Integrating Generative AI and Process Intelligence
May 28 2024 19:20 JST
NEC X Invests in Agtech Startup Verdi, Integrates AI-Powered Platform with NEC's Cropscope Smart Farming Initiative
May 23 2024 10:20 JST
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17 2024 10:19 JST
NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement
May 08 2024 09:24 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
April 24 2024 12:25 JST
More Press release >>

Latest Press Release

More Latest Release >>